ArticleJournal of clinical microbiology2010
Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern.
Article in Journal of clinical microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 74 citations in OpenAlex.
- Mucormycosis Caused byJournal of fungi (Basel, Switzerland) · 2025Review
- Clinical and Mycologic Characteristics of Emerging Mucormycosis Agent Rhizopus homothallicus.Emerging infectious diseases · 2023Article
- A case of COVID-19-associated rhino-orbito-cerebral mucormycosis caused byFrontiers in cellular and infection microbiology · 2022Review
- Quorum sensing-mediated inter-specific conidial anastomosis tube fusion between Colletotrichum gloeosporioides and C. siamense.IMA fungus · 2021Article
- Outbreaks of Mucorales and the Species Involved.Mycopathologia · 2020Review
- Rhino-orbital mucormycosis due to Apophysomyces ossiformis in a patient with diabetes mellitus: a case report.BMC infectious diseases · 2020Article
- Prolonged Outbreak of Candida krusei Candidemia in Paediatric Ward of Tertiary Care Hospital.Mycopathologia · 2020Article
- Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Article
- Mucormycosis of the Central Nervous System.Journal of fungi (Basel, Switzerland) · 2019Review
- Necrotizing fasciitis caused byIDCases · 2019Article
- Post-traumatic fatal disseminatedMedical mycology case reports · 2018Article
- Apophysomyces variabilis: draft genome sequence and comparison of predictive virulence determinants with other medically important Mucorales.BMC genomics · 2017Article
- Diagnostic difficulty identifyingJMM case reports · 2016Article
- Cutaneous mucormycosis postcosmetic surgery: A case report and review of the literature.Medicine · 2016Review
- Malassezia arunalokei sp. nov., a Novel Yeast Species Isolated from Seborrheic Dermatitis Patients and Healthy Individuals from India.Journal of clinical microbiology · 2016Article
- Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales.Antimicrobial agents and chemotherapy · 2015Article
- Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus.Journal of clinical microbiology · 2014Article
- Review
- Biology, systematics, and clinical manifestations of Zygomycota infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2014Review
- Isavuconazole therapy protects immunosuppressed mice from mucormycosis.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apophysomyces elegans is an emerging pathogen in India. We planned the present study to analyze the clinical pattern of the disease, to perform molecular strain typing, and to determine the in vitro activities of eight antifungal drugs against A. elegans. A total of 16 clinical and two environmental A. elegans isolates were included in the study. The clinical histories of the patients were noted. MICs or minimum effective concentrations (MECs) were determined for antifungal drugs by microdilution testing in accordance with CLSI standard M38-A2 guidelines. Of 16 patients, seven had rhino-cerebral, five had cutaneous, and three had renal zygomycosis. One patient had osteomyelitis. Uncontrolled diabetes was observed in 63% of the patients. Amplified fragment length polymorphism (AFLP) analysis divided the strains into two clearly different clades. The fingerprints of the environmental strains (including the type strain) were clearly different from those of the clinical strains. The MIC50s and MIC90s for amphotericin B, itraconazole, posaconazole, and isavuconazole were 2 and 4, 1 and 2, 0.5 and 1, and 2 and 4 μg/ml, respectively. The strains had high MICs for fluconazole, voriconazole, and echinocandins. The study indicates a possible change in the clinical pattern of zygomycosis due to A. elegans in India. The fungus caused not only cutaneous or subcutaneous infection but also other deep-seated infections, and the disease is commonly associated with uncontrolled diabetes. The AFLP patterns show a clear difference between environmental and clinical strains. Posaconazole is the most active drug against the isolates, followed by itraconazole. The MICs of amphotericin B against A. elegans were higher than those of the other drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.